<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145898</url>
  </required_header>
  <id_info>
    <org_study_id>Cosopt and OAG progression</org_study_id>
    <nct_id>NCT01145898</nct_id>
  </id_info>
  <brief_title>Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data</brief_title>
  <official_title>Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze Cosopt® in terms of its effects on ocular perfusion pressure and comprehensive
      ocular blood flow and in relation to visual field progression and optic nerve structural
      changes in an ongoing 3 year prospective study involving 120 patients with open angle
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To analyze Cosopt® in terms of its effects on ocular perfusion pressure and comprehensive
      ocular blood flow and in relation to visual field progression and optic nerve structural
      changes in an ongoing 3 year prospective study involving 120 patients with open angle
      glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change inOphthalmic Artery (OA) End Diastolic Velocity (EDV)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change in Ophthalmic Artery (OA) Vascular Resistance (RI)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Change in Ocular Perfusion Pressures (OPP)</measure>
    <time_frame>Baseline and 6 month visits</time_frame>
    <description>Measurement of change in ocular perfusion pressure, the pressure of blood flow to the eye minus the pressure of within the eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in OA PSV</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in OA EDV</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in OA RI</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in CRA PSV</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in CRA EDV</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in CRA RI</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular blood flow - central retinal arteries resistance index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year Change in OPP</measure>
    <time_frame>Baseline and 36 month visits</time_frame>
    <description>Measurement of change in ocular perfusion pressure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <description>Patients with Glaucoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Cosopt®, prostaglandin)</intervention_name>
    <description>We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.</description>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <other_name>Cosopt is a trade name drug which is a combination of dorzolamide and timolol.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Glaucoma patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 30 years or older.

          2. Diagnosis: confirmed open-angle glaucoma in at least one eye:

               1. glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry

               2. glaucomatous optic disc cupping

               3. agreement between two baseline exams for reliability

          3. Best corrected visual acuity at least 20/60 in at least one eye.

          4. Prior Humphrey visual fields demonstrate acceptable reliability standards.

        Exclusion Criteria:

          1. Extensive Humphrey visual field damage consisting of either a mean deviation (MD) &lt;
             -15 decibels or a clinically determined threat to fixation in both hemifields.

          2. Evidence of exfoliation or pigment dispersion.

          3. History of acute angle-closure or a narrow, occludable anterior chamber angle by
             gonioscopy.

          4. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).

          5. History or signs of intraocular trauma.

          6. Severe or potentially progressive retinal disease such as retinal degeneration,
             diabetic retinopathy, and retinal detachment.

          7. Any abnormality preventing reliable applanation tonometry.

          8. Current use of any ophthalmic or systemic steroid which may interfere with this
             investigation.

          9. Cataract surgery within the past year.

         10. Resting pulse &lt; 50 beats per minute.

         11. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alon Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine, Department of Ophthalmology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <results_first_submitted>September 20, 2013</results_first_submitted>
  <results_first_submitted_qc>January 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2014</results_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Cosopt</keyword>
  <keyword>blood flow</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dorzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment over 6 months. Hospital and area eye clinics</recruitment_details>
      <pre_assignment_details>observational study, patients were treated by their physician not by study personel, treatments/interventions were self-reported by the patients, treatment was not necessarily started at glaucoma diagnosis</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Trusopt</title>
          <description>Patients with glaucoma taking Trusopt or Cosopt alone or with prostaglandin for at least 6 months</description>
        </group>
        <group group_id="P2">
          <title>Prostaglandin Alone</title>
          <description>Patients with glaucoma taking prostaglandin alone for at least 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>6-month Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3-year Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>medication change by treating physician</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>glaucoma patients:There will be (as shown) differences in the number of subjects based upon the time of analysis due to patient loss, data of insufficient quality at visit, or change in the drug use during period of study (patient switched off treatment by their doctor) so the number of data points varies throughout the analysis by availability.</population>
      <group_list>
        <group group_id="B1">
          <title>Trusopt</title>
          <description>Patients with glaucoma taking Trusopt or Cosopt alone or with prostaglandin for at least 6 months</description>
        </group>
        <group group_id="B2">
          <title>Prostaglandin Alone</title>
          <description>Patients with glaucoma taking prostaglandin alone for at least 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.23" spread="6.78"/>
                    <measurement group_id="B2" value="65.25" spread="8.78"/>
                    <measurement group_id="B3" value="64.82" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="1.20"/>
                    <measurement group_id="O2" value="-.30" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There will be (as shown) differences in the number of subjects based upon the time of analysis due to patient loss, data of insufficient quality at visit, or change in the drug use during period of study (patient switched off treatment by their doctor) so the number of data points varies throughout the analysis by availability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.6261</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change inOphthalmic Artery (OA) End Diastolic Velocity (EDV)</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change inOphthalmic Artery (OA) End Diastolic Velocity (EDV)</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".63"/>
                    <measurement group_id="O2" value="-.03" spread=".39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.6081</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Ophthalmic Artery (OA) Vascular Resistance (RI)</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Ophthalmic Artery (OA) Vascular Resistance (RI)</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.011" spread=".020"/>
                    <measurement group_id="O2" value=".002" spread=".008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1822</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread=".34"/>
                    <measurement group_id="O2" value="-.045" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2383</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread=".16"/>
                    <measurement group_id="O2" value="-.12" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2383</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.012" spread=".012"/>
                    <measurement group_id="O2" value=".005" spread=".008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1564</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-month Change in Ocular Perfusion Pressures (OPP)</title>
        <description>Measurement of change in ocular perfusion pressure, the pressure of blood flow to the eye minus the pressure of within the eye.</description>
        <time_frame>Baseline and 6 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Change in Ocular Perfusion Pressures (OPP)</title>
          <description>Measurement of change in ocular perfusion pressure, the pressure of blood flow to the eye minus the pressure of within the eye.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.30" spread="2.02"/>
                    <measurement group_id="O2" value="-2.88" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2265</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in OA PSV</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in OA PSV</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.62" spread="2.41"/>
                    <measurement group_id="O2" value=".07" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.4645</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in OA EDV</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in OA EDV</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.58" spread=".58"/>
                    <measurement group_id="O2" value="-.98" spread=".35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.5998</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in OA RI</title>
        <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in OA RI</title>
          <description>Measurement of change in ocular blood flow - ophthalmic artery resistance index</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".042" spread=".026"/>
                    <measurement group_id="O2" value=".036" spread=".013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.8119</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in CRA PSV</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in CRA PSV</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.66" spread=".61"/>
                    <measurement group_id="O2" value=".37" spread=".40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1319</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in CRA EDV</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in CRA EDV</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.21" spread=".21"/>
                    <measurement group_id="O2" value=".12" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0199</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in CRA RI</title>
        <description>Measurement of change in ocular blood flow - central retinal arteries resistance index</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in CRA RI</title>
          <description>Measurement of change in ocular blood flow - central retinal arteries resistance index</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".007" spread=".024"/>
                    <measurement group_id="O2" value=".013" spread=".014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.7597</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-year Change in OPP</title>
        <description>Measurement of change in ocular perfusion pressure</description>
        <time_frame>Baseline and 36 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trusopt</title>
            <description>Patients taking trusopt or cosopt alone or with prostaglandin</description>
          </group>
          <group group_id="O2">
            <title>Prostaglandin Alone</title>
            <description>Patients taking prostaglandin alone</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Change in OPP</title>
          <description>Measurement of change in ocular perfusion pressure</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.91" spread="2.74"/>
                    <measurement group_id="O2" value="-1.43" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2528</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not assessed/collected as part of this study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glaucoma Patients</title>
          <description>Patients with Glaucoma</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of participants at various time-points limited the power of analysis in our estimation, as did patients who changed medications and therefore further limited analysis options at various time-points.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alon Harris</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-00177</phone>
      <email>alharris@indiana.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

